All In Biotech

NDA 020358 · Glaxosmithkline

Wellbutrin Sr

Bupropion Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Oct 4, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

440

96 Phase 3, 24 recruiting

FAERS reports

79,944

42,547 serious, 4,101 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older [see Warnings and Precautions ( 5.1 )] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions ( 5.1 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal...

What it is approved for

From the label in effect Nov 5, 2025.

WELLBUTRIN SR (bupropion hydrochloride) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies ( 14 )] . The efficacy of WELLBUTRIN SR in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo‑controlled trial [see Clinical Studies ( 14 )] . WELLBUTRIN SR is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD). ( 1 )

Mechanism: The exact mechanism of the antidepressant action of bupropion is not known but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • WELLBUTRIN SR · BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • WELLBUTRIN SR · BUPROPION HYDROCHLORIDE 50MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • WELLBUTRIN SR · BUPROPION HYDROCHLORIDE 200MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • WELLBUTRIN SR · BUPROPION HYDROCHLORIDE 100MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.

All 440 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,772
  • nausea6,333
  • fatigue6,166
  • headache5,763
  • depression5,348
  • pain4,701
  • anxiety4,589
  • dizziness4,049
  • off label use4,007
  • insomnia3,481
  • diarrhoea3,142
  • vomiting2,950

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,333
20052,895
20062,621
20072,171
20081,793
20092,373
20102,865
20112,774
20123,158
20132,680
20142,895
20154,531
20165,256
20174,228
20184,133
20194,677
20204,370
20213,921
20224,221
20233,879
20244,460
20253,839
20262,870

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Wellbutrin SR (Bupropion HCl)

2024 spending

$5.2M

Beneficiaries

1,307

6,091 claims

Per beneficiary

$3,975

$8.88 per unit

View as table
YearSpending
2020$6,174,264
2021$5,951,784
2022$5,737,310
2023$5,740,637
2024$5,195,533

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,202 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.